DATE: January 23, 2006

TO: State Survey Agency Directors

FROM: Director
Survey and Certification Group

SUBJECT: State Survey Agency (SA) Responsibilities for 2006 Regarding Gynecologic Cytology Proficiency Testing (PT) under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and Additional Program Information—UPDATE

Letter Summary

- **Purpose:** This memo updates S&C Memo #05-11 dated 12/16/04. It provides further guidance for assessing cytology laboratory compliance with CLIA requirements for cytology PT.

- **Educational Approach Continued in 2006:** For CY 2006 we are continuing the educational approach we previously adopted in 2005 for the implementation of national PT. This means that laboratories will not fail cytology PT, have deficiencies cited, or have sanctions imposed against their CLIA certificate provided they:
  1. Enroll all affected individuals in a Centers for Medicare & Medicaid Services (CMS) approved testing program for the CY 2006 testing cycle, and
  2. Ensure that all such individuals are tested in a timely manner within 2006, in accordance with the regulatory protocol. The regulatory protocol under 42 CFR 493.855 identifies the extent to which additional testing, education, or limitations must be put in place with regard to individuals who do not pass the test initially.

- **2005 Testing:** In early 2006 we will complete the implementation and review of CY 2005 testing. S&C memo #05-11 provided that, in the first year of testing (2005), laboratories had until April 2, 2006 to ensure that all affected individuals were tested at least once for the 2005 testing cycle. The fact that only 4% of laboratories have needed the extra time is testimony to the diligence and capability of the laboratory community.

- **Additional Choice for 2006 Testing Cycle:** In addition to the Midwest Institute for Medical Education (MIME) and the State of Maryland, we have approved a third PT program, the College of American Pathologists (CAP), for 2006.

- **Future Developments:** CMS and the Centers for Disease Control and Prevention (CDC) are engaging a workgroup under the auspices of the Secretary’s Clinical Laboratory Improvement Advisory Committee (CLIAc) to advise us on scoring methods and standards to address issues of concern and optimize proficiency tests. We look forward to working with the professional community to promote the best possible health care.

- **The CLIA Web site** at: www.cms.hhs.gov/clia includes current cytology PT performance data and policies, as well as responses to issues of concern.
Background

The CLIA statute requires the “periodic confirmation and evaluation of the proficiency of individuals involved in screening or interpreting cytological preparations, including announced and unannounced on-site PT of such individuals, with such testing to take place, to the extent practicable under normal working conditions.” See 42 USC sec. 263a(f)(4)(B)(iv) section 353(f)(4)(B)(iv) of the Public Health Service Act.

The CLIA regulations that implement this statutory provision require cytology laboratories and individuals who examine gynecological cytology specimens to enroll in a CMS-approved cytology PT program and achieve a passing score, annually. Specifically:

- 42 CFR 493.801 specifies that, “Each laboratory must enroll in a proficiency testing (PT) program that meets the criteria in subpart I of this part and is approved by HHS. The laboratory must enroll in an approved program or programs for each of the specialties and subspecialties for which it seeks certification.”

- 42 CFR 493.855 provides that, “To participate successfully in a cytology proficiency testing program for gynecologic examinations . . . .” “(a) The laboratory must ensure that each individual engaged in the examination of gynecologic preparations is enrolled in a proficiency testing program approved by CMS by January 1, 1995, if available in the State in which he or she is employed [applicable to Maryland]. The laboratory must ensure that each individual is tested at least once per year and obtains a passing score [universally applicable].”

CMS-Approved PT Programs for 2006

- The State of Maryland Cytology Proficiency Testing Program is approved to test the proficiency of physicians and cytotechnologists who examine Pap smears from Maryland residents.
- The Midwest Institute for Medical Education (MIME) has met the statutory and regulatory requirements for CMS approval as a national cytology PT program for both CY 2005 and CY 2006.
- The College of American Pathologists (CAP) has been approved for national cytology PT beginning CY 2006.

Educational Approach in 2006

For 2006, we will continue the “educational approach” for cytology PT that we previously adopted for 2005. This means laboratories will not fail cytology PT, have deficiencies cited, or have sanctions imposed against their CLIA certificate provided they:

1. Enroll all affected individuals (i.e., cytotechnologists and pathologists) in a CMS-approved testing program for the CY 2006 testing cycle, and
2. Ensure that all such individuals are tested in a timely manner within 2006, in accordance with the regulatory protocol. The regulatory protocol under 42 CFR 493.855 identifies the extent to which additional testing, education or limitations must be put in place with regard to individuals who do not pass the test initially. See detailed information below and in the regulations.
Continuation of the educational approach will permit laboratories and individuals to enhance their training and education, as well as make the best decisions for future testing. It also provides CMS the opportunity to compile and evaluate the performance data from 2005. Together with the CDC we are engaging a workgroup under the auspices of the Secretary’s Clinical Laboratory Improvement Advisory Committee (CLIAC) to examine first-year test results, scoring methods, and standards to address issues of concern and optimize PT.

**CLIAC Cytology PT Work Group**

Representatives of CDC and CMS have been in communication with the cytology pathologist and cytotechnologist associations to discuss the process in which these organizations will have direct input into our review of current operational procedures and current standards for PT. Under the auspices of the Secretary’s CLIAC, a workgroup will advise us on scoring methods and standards to optimize gynecological cytology examination. Workgroup members with appropriate expertise will provide vital input to the full Advisory Committee on how we might accelerate the process of identifying how the cytology PT requirements might be improved.

**Survey Protocols for Compliance with Cytology PT**

The attachment to this memorandum contains the special survey protocols for 2006.

**Communications**

All questions regarding this correspondence should be directed to CMS’ Division of Laboratory Services at (410) 786-3531. We will post contacts for CMS-approved PT organizations on the CMS website at [www.cms.hhs.gov/clia](http://www.cms.hhs.gov/clia), as well as other information regarding cytology PT, including updated performance data, policies, and CMS responses to concerns.

**Effective Date:** The effective date of this memorandum is January 1, 2006. All surveys conducted on or after this date must incorporate the provisions of this memorandum.

**Training:** The information contained in this memo should be shared immediately with all CLIA survey and certification staff and managers who have responsibility for the oversight of gynecologic cytology laboratories.

/s/
Thomas E. Hamilton

cc: Survey and Certification Regional Office Management
In the conduct of surveys beginning January 1, 2006, State Survey Agencies (SAs) must accomplish the following:

- **Enrollment:** Confirm by review of enrollment documentation that the individuals examining gynecologic cytology slides are enrolled in a CMS-approved cytology PT program for this calendar year and that all laboratory cytology testing sites are enrolled.

- **Testing:** Inquire of the laboratory director as to the status and outcomes of each individual’s testing to ensure that the laboratory is following the regulatory protocol.
  - **NOTE:** For laboratories that will not be surveyed in 2006, the SAs will receive guidance from CMS Central Office (CO), based on monitoring of enrollment and testing performance data from the Survey & Certification Group.

- **Exempt States & Approved Accrediting Organizations (AOs):** Exempt and accredited laboratories will be overseen by their respective States or AOs and CO, consistent with these protocols.

- **System of Re-Testing:** Confirm that individuals who fail the initial proficiency test are being re-tested timely in conformance with the procedures of 42 CFR 493.855.

- **Additional Systems of Controls:** Confirm that the laboratory has in place procedures for and documentation of the review of slides examined by individuals who have failed a second test and their education in the area of failure. There should also be procedures for and documentation of appropriate follow-up of individuals who fail a third test; i.e., prohibition of screening following test failure notification and acquisition of 35 CEUs in a formal pertinent cytology educational program. These situations are extremely rare.

- **Verification of Compliance:** For laboratories that will not be surveyed in 2006, CO will monitor their performance and provide additional guidance to the CMS regional offices.

**Enforcement When the Educational Approach Fails**

The CMS regional office, in conjunction with the SA, will initiate intermediate sanctions that may include Civil Money Penalties of up to $10,000, limitation of the laboratory’s CLIA certificate for cytology, and, if applicable and serious, suspension of the laboratory’s Medicare and Medicaid payments for gynecologic cytology testing in accordance with subpart R of the CLIA regulations if the laboratory fails to accomplish any of the following:

- **Ensure Enrollment:** Fails to enroll all gynecologic cytology testing sites in a CMS-approved cytology PT program for each calendar year (CY 2005, if applicable, and CY 2006);

- **Ensure Testing in 2006:** Fails to ensure that all individuals examining gynecologic cytology slides in 2006 are enrolled in a CMS-approved cytology PT program and are tested in a timely manner within 2006, in accordance with the regulatory protocol. The regulatory protocol under 42 CFR 493.855 identifies the extent to which additional testing, education or limitations must be put in place with regard to individuals who do not pass the test initially.¹

---

¹ **NOTE:** CMS will not take enforcement action for failure to complete a cytology proficiency test with respect to any otherwise-qualified individual who meets the CMS criteria for special circumstances (such as certain newly-hired individuals), as described in the “Cytology PT Informational Supplement 2006” posted on the CMS website at [www.cms.hhs.gov/clia](http://www.cms.hhs.gov/clia).
• **Ensure Education, Re-testing in 2006:** Fails to ensure that an individual who fails a cytology PT test takes any required additional education or remedial actions, and is retested, as specified in the CLIA requirements, if such individual continues to examine slides for the laboratory.

• **Complete 2005 Testing:** Fails to ensure that the 2005 testing has occurred by April 2, 2006 (as described in S&C memo #05-11, 12/16/04). This applies to individuals who were subject to the 2005 testing cycle but who were not tested in CY 2005 (and who are not excused/excepted to examine slides)\(^1\).

In early 2006 any accredited or non-accredited laboratories that did not fulfill the 2005 testing requirements (see S&C Memo #05-11) will be notified via letter of the problem and the action they can take by April 2, 2006 to prevent potential sanction(s).